Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma

Nobuhiro Nitori, Yoshinori Ino, Yukihiro Nakanishi, Tesshi Yamada, Kazufumi Honda, Kazuyoshi Yanagihara, Tomoo Kosuge, Yae Kanai, Masaki Kitajima, Setsuo Hirohashi, Tsuo Tirchashi

研究成果: Article

111 引用 (Scopus)

抄録

Tissue factor (TF) is a transmembrane glycoprotein that plays roles in the blood coagulation and intracellular signaling pathways, and has also been suggested to modulate the biological behavior of cancer cells. In order to examine the clinicopathologic significance of TF expression in pancreatic ductal adenocarcinoma, TF expression was determined by immunohistochemistry using a newly raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection of pancreatic ductal adenocarcinoma. According to the incidence of tumor cell immunopositivity, patients were divided into "negative TF" (0%), "weak TF" (<25%), or "high TF" (25% or more) groups, which accounted for 11.6% (n = 13), 44.2% (n = 50), and 44.2% (n = 50) of the total, respectively. Increased TF expression was correlated with the extent of the primary tumor (P = 0.0043), lymph node metastasis (P = 0.0043), lymphatic distant metastasis (P = 0.0039), advanced tumor-node-metastasis stage (P = 0.0002), and high tumor grade (P = 0.0164). Multivariate analysis using the Cox proportional hazards model showed that high TF expression was an independent negative predictor for survival (hazard ratio, 2.014; P = 0.0076). Moreover, patients with TF-negative tumors had a significantly better prognosis even if lymph node metastasis was present (P < 0.0001). We also showed that TF knockdown by RNA interference suppressed the invasiveness of a pancreatic adenocarcinoma cell line in vitro. These results indicate that TF expression may contribute to the aggressiveness of pancreatic ductal adenocarcinoma by stimulating tumor invasiveness, and that evaluation of the primary tumor for TF expression may identify patients with a poor prognosis.

元の言語English
ページ(範囲)2531-2539
ページ数9
ジャーナルClinical Cancer Research
11
発行部数7
DOI
出版物ステータスPublished - 2005 4 1
外部発表Yes

Fingerprint

Thromboplastin
Adenocarcinoma
Neoplasms
Neoplasm Metastasis
Lymph Nodes
Lymphatic Metastasis
Blood Coagulation
RNA Interference
Proportional Hazards Models
Glycoproteins
Multivariate Analysis
Immunohistochemistry
Monoclonal Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

これを引用

Nitori, N., Ino, Y., Nakanishi, Y., Yamada, T., Honda, K., Yanagihara, K., ... Tirchashi, T. (2005). Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clinical Cancer Research, 11(7), 2531-2539. https://doi.org/10.1158/1078-0432.CCR-04-0866

Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. / Nitori, Nobuhiro; Ino, Yoshinori; Nakanishi, Yukihiro; Yamada, Tesshi; Honda, Kazufumi; Yanagihara, Kazuyoshi; Kosuge, Tomoo; Kanai, Yae; Kitajima, Masaki; Hirohashi, Setsuo; Tirchashi, Tsuo.

:: Clinical Cancer Research, 巻 11, 番号 7, 01.04.2005, p. 2531-2539.

研究成果: Article

Nitori, N, Ino, Y, Nakanishi, Y, Yamada, T, Honda, K, Yanagihara, K, Kosuge, T, Kanai, Y, Kitajima, M, Hirohashi, S & Tirchashi, T 2005, 'Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma', Clinical Cancer Research, 巻. 11, 番号 7, pp. 2531-2539. https://doi.org/10.1158/1078-0432.CCR-04-0866
Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K その他. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clinical Cancer Research. 2005 4 1;11(7):2531-2539. https://doi.org/10.1158/1078-0432.CCR-04-0866
Nitori, Nobuhiro ; Ino, Yoshinori ; Nakanishi, Yukihiro ; Yamada, Tesshi ; Honda, Kazufumi ; Yanagihara, Kazuyoshi ; Kosuge, Tomoo ; Kanai, Yae ; Kitajima, Masaki ; Hirohashi, Setsuo ; Tirchashi, Tsuo. / Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. :: Clinical Cancer Research. 2005 ; 巻 11, 番号 7. pp. 2531-2539.
@article{c75aedb825b54813bd199993935bc1b7,
title = "Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma",
abstract = "Tissue factor (TF) is a transmembrane glycoprotein that plays roles in the blood coagulation and intracellular signaling pathways, and has also been suggested to modulate the biological behavior of cancer cells. In order to examine the clinicopathologic significance of TF expression in pancreatic ductal adenocarcinoma, TF expression was determined by immunohistochemistry using a newly raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection of pancreatic ductal adenocarcinoma. According to the incidence of tumor cell immunopositivity, patients were divided into {"}negative TF{"} (0{\%}), {"}weak TF{"} (<25{\%}), or {"}high TF{"} (25{\%} or more) groups, which accounted for 11.6{\%} (n = 13), 44.2{\%} (n = 50), and 44.2{\%} (n = 50) of the total, respectively. Increased TF expression was correlated with the extent of the primary tumor (P = 0.0043), lymph node metastasis (P = 0.0043), lymphatic distant metastasis (P = 0.0039), advanced tumor-node-metastasis stage (P = 0.0002), and high tumor grade (P = 0.0164). Multivariate analysis using the Cox proportional hazards model showed that high TF expression was an independent negative predictor for survival (hazard ratio, 2.014; P = 0.0076). Moreover, patients with TF-negative tumors had a significantly better prognosis even if lymph node metastasis was present (P < 0.0001). We also showed that TF knockdown by RNA interference suppressed the invasiveness of a pancreatic adenocarcinoma cell line in vitro. These results indicate that TF expression may contribute to the aggressiveness of pancreatic ductal adenocarcinoma by stimulating tumor invasiveness, and that evaluation of the primary tumor for TF expression may identify patients with a poor prognosis.",
author = "Nobuhiro Nitori and Yoshinori Ino and Yukihiro Nakanishi and Tesshi Yamada and Kazufumi Honda and Kazuyoshi Yanagihara and Tomoo Kosuge and Yae Kanai and Masaki Kitajima and Setsuo Hirohashi and Tsuo Tirchashi",
year = "2005",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0866",
language = "English",
volume = "11",
pages = "2531--2539",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma

AU - Nitori, Nobuhiro

AU - Ino, Yoshinori

AU - Nakanishi, Yukihiro

AU - Yamada, Tesshi

AU - Honda, Kazufumi

AU - Yanagihara, Kazuyoshi

AU - Kosuge, Tomoo

AU - Kanai, Yae

AU - Kitajima, Masaki

AU - Hirohashi, Setsuo

AU - Tirchashi, Tsuo

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Tissue factor (TF) is a transmembrane glycoprotein that plays roles in the blood coagulation and intracellular signaling pathways, and has also been suggested to modulate the biological behavior of cancer cells. In order to examine the clinicopathologic significance of TF expression in pancreatic ductal adenocarcinoma, TF expression was determined by immunohistochemistry using a newly raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection of pancreatic ductal adenocarcinoma. According to the incidence of tumor cell immunopositivity, patients were divided into "negative TF" (0%), "weak TF" (<25%), or "high TF" (25% or more) groups, which accounted for 11.6% (n = 13), 44.2% (n = 50), and 44.2% (n = 50) of the total, respectively. Increased TF expression was correlated with the extent of the primary tumor (P = 0.0043), lymph node metastasis (P = 0.0043), lymphatic distant metastasis (P = 0.0039), advanced tumor-node-metastasis stage (P = 0.0002), and high tumor grade (P = 0.0164). Multivariate analysis using the Cox proportional hazards model showed that high TF expression was an independent negative predictor for survival (hazard ratio, 2.014; P = 0.0076). Moreover, patients with TF-negative tumors had a significantly better prognosis even if lymph node metastasis was present (P < 0.0001). We also showed that TF knockdown by RNA interference suppressed the invasiveness of a pancreatic adenocarcinoma cell line in vitro. These results indicate that TF expression may contribute to the aggressiveness of pancreatic ductal adenocarcinoma by stimulating tumor invasiveness, and that evaluation of the primary tumor for TF expression may identify patients with a poor prognosis.

AB - Tissue factor (TF) is a transmembrane glycoprotein that plays roles in the blood coagulation and intracellular signaling pathways, and has also been suggested to modulate the biological behavior of cancer cells. In order to examine the clinicopathologic significance of TF expression in pancreatic ductal adenocarcinoma, TF expression was determined by immunohistochemistry using a newly raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection of pancreatic ductal adenocarcinoma. According to the incidence of tumor cell immunopositivity, patients were divided into "negative TF" (0%), "weak TF" (<25%), or "high TF" (25% or more) groups, which accounted for 11.6% (n = 13), 44.2% (n = 50), and 44.2% (n = 50) of the total, respectively. Increased TF expression was correlated with the extent of the primary tumor (P = 0.0043), lymph node metastasis (P = 0.0043), lymphatic distant metastasis (P = 0.0039), advanced tumor-node-metastasis stage (P = 0.0002), and high tumor grade (P = 0.0164). Multivariate analysis using the Cox proportional hazards model showed that high TF expression was an independent negative predictor for survival (hazard ratio, 2.014; P = 0.0076). Moreover, patients with TF-negative tumors had a significantly better prognosis even if lymph node metastasis was present (P < 0.0001). We also showed that TF knockdown by RNA interference suppressed the invasiveness of a pancreatic adenocarcinoma cell line in vitro. These results indicate that TF expression may contribute to the aggressiveness of pancreatic ductal adenocarcinoma by stimulating tumor invasiveness, and that evaluation of the primary tumor for TF expression may identify patients with a poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=20244366228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244366228&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0866

DO - 10.1158/1078-0432.CCR-04-0866

M3 - Article

C2 - 15814630

AN - SCOPUS:20244366228

VL - 11

SP - 2531

EP - 2539

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -